| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1068965627 |
| P356 | DOI | 10.2119/MOLMED.2013.00108 |
| P932 | PMC publication ID | 3883970 |
| P698 | PubMed publication ID | 24166682 |
| P5875 | ResearchGate publication ID | 258117022 |
| P2093 | author name string | Maha Hussain | |
| Lakshmi P Kunju | |||
| Dafydd Thomas | |||
| Mark L Day | |||
| Petros D Grivas | |||
| Kathleen C Day | |||
| Monica Liebert | |||
| Alyssa Paul | |||
| Andreas Karatsinides | |||
| Iya Owainati | |||
| Nazia Shakir | |||
| P2860 | cites work | Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer | Q56749926 |
| Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer | Q73311092 | ||
| Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome | Q80062040 | ||
| Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial | Q80406288 | ||
| Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder | Q82584712 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 | ||
| Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system | Q33747967 | ||
| Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors | Q33767107 | ||
| Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships | Q34045509 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors | Q34625315 | ||
| Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells | Q34743802 | ||
| Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy | Q34866510 | ||
| Urothelial carcinomas: a focus on human epidermal receptors signaling | Q35172558 | ||
| Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family | Q35173073 | ||
| Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. | Q36185012 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis | Q36238822 | ||
| HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. | Q36693285 | ||
| Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer | Q37122307 | ||
| Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. | Q37659109 | ||
| Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. | Q38419743 | ||
| Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib | Q39320168 | ||
| Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation | Q39394737 | ||
| The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines | Q39422598 | ||
| Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer | Q39434209 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib | Q40033522 | ||
| Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy | Q40167169 | ||
| Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy | Q40170042 | ||
| Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. | Q40210754 | ||
| Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression | Q40318384 | ||
| Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma | Q40832646 | ||
| Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice | Q40971116 | ||
| Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3 | Q41107277 | ||
| Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines | Q41778604 | ||
| Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells | Q42816083 | ||
| Clinical significance of Her2/neu overexpression in urothelial carcinomas. | Q43056122 | ||
| A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. | Q46033801 | ||
| Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? | Q46947574 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 367-376 | |
| P577 | publication date | 2013-11-08 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer | |
| P478 | volume | 19 |
| Q34081624 | A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. |
| Q38383646 | Animal models for bladder cancer: The model establishment and evaluation (Review). |
| Q89748843 | COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin |
| Q39198033 | Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. |
| Q90101340 | Dacomitinib: First Global Approval |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q50064748 | Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer |
Search more.